Lakefront Biotherapeutics NV current report, Q2 FY2018

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of June 2018. The filing serves to incorporate by reference a press release dated June 15, 2018, issued by the registrant. Galapagos NV is a foreign private issuer incorporated in Belgium.

Financial Metrics

The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing acts solely as a conduit for the attached press release (Exhibit 99.1), the content of which is not included in the input text.

Material Changes

No material changes regarding financial performance or operations are detailed in the text of this Form 6-K. The document references a press release but does not summarize its contents or disclose specific operational updates.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, future guidance, risk factors, or details on contingencies. It strictly references the incorporation of the June 15, 2018, press release into the company's Registration Statements on Forms F-3 and S-8.

Key Facts for Investor Verification

  • Verify the actual content of the June 15, 2018 press release (Exhibit 99.1) to understand the material event triggering this filing.
  • Confirm the registrant is Galapagos NV, noting the discrepancy with the "Lakefront Biotherapeutics NV" name in the request metadata.
  • Check the referenced Registration Statements (Forms F-3 and S-8) for the full context of the incorporated information.
  • Note that this document contains no standalone financial figures.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.